Payment overview · 2025
General Payments
$1,011.01
50 reported records · 19 companies
Healthcare provider profile · identity verified
Mark A Vann, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DECHERD, TN · NPI 1194036327
Verified facts
What the public records show
CMS Open Payments records show Mark A Vann, FNP-BC received $1,011.01 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.04 | 13.8% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $124.92 | 12.4% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $91.08 | 9.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.06 | 8.8% | 5 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $83.85 | 8.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.60 | 7.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.57 | 5.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.24 | 5.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.44 | 4.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.35 | 4.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.38 | 4.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.87 | 3.4% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $29.54 | 2.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.95 | 2.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.77 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.08 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.94 | 1.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.90 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.43 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,011.01 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $137.08 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $124.92 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.06 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.02 | 5 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $83.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.72 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.57 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.02 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| TRIPTODUR Normalized: triptodur |
Drug | Azurity Pharmaceuticals, Inc. | $33.87 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 454 | 85 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 363 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 205 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 151 | 40 |
| Prednisone | Prednisone | 139 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 34 |
| Pregabalin | Pregabalin | 130 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 39 |
| Montelukast Sodium | Montelukast Sodium | 124 | 30 |
| Valsartan | Valsartan | 117 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 33 |
| Alprazolam | Alprazolam | 113 | 29 |
| Omeprazole | Omeprazole | 111 | 34 |
| Furosemide | Furosemide | 110 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 36 |
| Lisinopril | Lisinopril | 98 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 29 |
| Losartan Potassium | Losartan Potassium | 88 | 29 |
| Famotidine | Famotidine | 85 | 19 |
| Trazodone Hcl | Trazodone Hcl | 84 | 30 |
| Sertraline Hcl | Sertraline Hcl | 78 | 15 |
| Simvastatin | Simvastatin | 71 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 26 |
| Promethazine Hcl | Promethazine Hcl | 67 | 27 |
| Metformin Hcl Er | Metformin Hcl | 66 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 12 |
| Ibuprofen | Ibuprofen | 58 | 18 |
| Farxiga | Dapagliflozin Propanediol | 57 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 19 |
| Bupropion Xl | Bupropion Hcl | 51 | 18 |
| Meloxicam | Meloxicam | 51 | 19 |
| Azithromycin | Azithromycin | 49 | 36 |
| Ozempic | Semaglutide | 49 | 18 |
| Potassium Chloride | Potassium Chloride | 49 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 18 |
| Atenolol | Atenolol | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Methocarbamol | Methocarbamol | 39 | 14 |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Carvedilol | Carvedilol | 35 | 13 |
| Estradiol | Estradiol | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 22 |
| Metformin Hcl | Metformin Hcl | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 21 |
| Topiramate | Topiramate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 21 |
| Finasteride | Finasteride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 12 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Cephalexin | Cephalexin | 21 | 16 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,011.01 · 50 records | ABBVIE INC. | AIRSUPRA, AURYON LASER SYSTEM 100-120 VAC, Auvelity, BREZTRI, CAPLYTA, FARXIGA, GEMTESA, JOURNAVX, MINIMED 780G, MOUNJARO, NEFFY, NURTEC ODT, QULIPTA, RECORLEV, REXULTI, TRIPTODUR, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, XYOSTED, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error